Home > News Center
Contact Us
Shanghai BravoBio Co., Ltd.
Add:Suite 14E, Building #5, Haifu Garden, 1365 Dongfang Road, Lujiazui Financial and Trade Zone, Shanghai 200127, China
Tel: +86 21 2025 5516
Fax: +86 21 2025 5517
Email: bd@bravobio.com
News Center
NIH may start Ebola vaccine trial as early as September
Aug. 4, 2014
The U.S. National Institutes of Health may start phase I clinical trial for an Ebola vaccine as early as September, waiting for approval by FDA. Developed by the National Institute of Allergy and Infectious Diseases' (NIAID) Vaccine Research Center, the vaccine is a recombinant chimpanzee adenovirus vector vaccine inserted with two Ebola genes. The NIAID said the vaccine has recently shown promise in a primate model.
EMA accepted Prevar expansion in adults
Aug. 12, 2014
The top 5 vaccines are namely, pfizer's Prevanar (a pneumococcal 13-valent conjugated vaccine), Sinofi's Pantocel (Diphtheria, pertussis/whooping cough; tetanus; polio; Haemophilus influenzae type B), Merck's Gadasil (Human papillomavirus), Sinofi's Fluzone (Influenza) and GSK's Pediarix (Diphtheria; tetanus; pertussis/whooping cough; hepatitis B; polio). Pfizer's Prevanar is now taking the lead with $3.76 billion sale in 2013 and is expected to widen its lead with sales growing more than 61% over the next 5+ years, predicted by EvaluatePharma.
Affiris Parkison's vaccine candidate succeeded in phase I
Aug. 13, 2014
Affiris recently announced that its vaccince candidate for Parkinson's disease suceeded in Phase I trial. In the study, PD01A was administered at two different doses to two groups of 12 patients each, and both doses were safe and well tolerated.
Pfizer's prevnar approved for use in adults of 65+
Aug. 15, 2014
Pfizer's Prevnar 13 has got US CDC's recommendation for use in adults 65, even those who have previously received Merck's Pneumovax. Adults who have never had a pneumococcal shot should receive a dose of Prevnar followed by a dose of Merck's vaccine. This approval could bring pfizer additional sales of $2 billion in peak.
FDA approved first needle-free injection system for flu vaccines
Aug. 21, 2014
FDA recently approved PharmaJet's Needle-Free Injector for the delivery of bioCSL's seasonal flu vaccine. The injector delivers the vaccine by a narrow but precise fluid stream that penetrates the skin in about one-tenth of a second.
Mutated poliovirus may resist vaccine protection
Sep. 1, 2014
Scientists recently discovered a mutated virus in polio victims of a 2010 outbreak in Congo which infected 445 people and killed 209. The mutated virus seemed to resist the vaccine protection. Surprisingly, half of the patients claimed to have received the recommended three vaccination dosages.
FDA gives green light to Ebola vaccine development
Sep. 4, 2014
As the death toll caused by Ebola virus surpasses 1,900 victims, FDA now wants to fast-track Ebola vaccine development. FDA recently gave green light to J&J, pushing it to test the jab in clinical trials in early 2015. FDA also gave the green light to NewLink Genetics to go ahead with Phase 1 clinical trials.
GSK's Ebola vaccine showed no adverse effects yet in phase I trial
Sep. 23, 2014
GSK's experimental Ebola vaccine is being tested in a phase I trial at the U.S. National Institutes of Health. 10 of the 20 volunteers have been vaccinated, with no major side effects found so far.
Merck acquired Sigma-Aldrich's global lab services with $17B buyout
Sep. 23, 2014
Merck KGaA just acquired Sigma-Aldrich's life sciences services for $17 billion. Merck paid Sigma-Aldrich $140 a share with a 37% premium over its Friday close. The acquisition will not only expand Merck Millipore's services of providing academic and industry lab clients with its research products, but also beef up Merck KGaA's manufacturing services side.
Previous 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 Next